Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the ...

Arcus Biosciences’ quemliclustat receives US FDA orphan drug designation to treat pancreatic cancer: Hayward, California Tuesday, July 15, 2025, 13:00 Hrs [IST] Arcus Bioscience ...

The Phase 3 study evaluating quemliclustat plus chemotherapy as a first-line treatment for metastatic pancreatic cancer is ...

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Corcept Therapeutics (CORT-Q) from The Globe and Mail including charting and trades.

In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously delivered immunotherapeutic agent, has a two-year overall survival rate of 21.9% ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma ...

Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, ...